XML 48 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Tax Expense (Benefit)
The provision for income taxes consists of the following (in thousands):
Year Ended December 31,
20242023
Current:
Federal$— $— 
State(12)(33)
Total current(12)(33)
Deferred:
Federal— — 
State— — 
Total deferred— — 
Income tax expense$(12)$(33)
Schedule of Effective Income Tax Rate Reconciliation
The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:
Year Ended December 31,
20242023
Federal statutory tax rate21.0 %21.0 %
State income taxes, net of federal tax benefits2.2 %2.2 %
Research and development tax credits0.1 %0.1 %
Stock compensation(5.9)%(3.4)%
Non-deductible expenses(2.5)%(1.4)%
Change in valuation allowance(15.2)%(18.5)%
Other— %(0.1)%
Effective tax rate(0.3)%(0.1)%
Schedule of Deferred Tax Assets and Liabilities If the Company’s judgment changes and it is determined
that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense (in thousands).
December 31,
20242023
Deferred tax assets:
Net operating loss carryforwards$35,348 $32,479 
Research and development tax credits2,360 2,353 
Accruals, reserves and other955 1,119 
Interest expense2,785 2,547 
Indefinite lived assets276 300 
Stock compensation598 1,391 
Lease liability681 925 
Capitalization of research and experimentation costs2,942 2,929 
Total gross deferred tax assets45,945 44,043 
Less: valuation allowance(45,237)(42,942)
Deferred tax assets, net708 1,101 
Deferred tax liabilities:
Right of use assets(592)(814)
Basis differences in fixed and intangible assets(116)(287)
Deferred tax liabilities(708)(1,101)
Net deferred tax assets$— $— 
Schedule of Valuation Allowance
Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2024 and 2023, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, and capitalization of research and experimentation costs were as follows (in thousands):
December 31,
20242023
Valuation allowance at the beginning of the year$42,942 $38,567 
Increases recorded to income tax provision2,295 4,375 
Valuation allowance at the end of the year$45,237 $42,942